Latest News
The Next Era of Cardiorenal Care Is Precision Fluid Management
Medicine has become increasingly specialized over the past several decades, driving tremendous advances in our ability to diagnose and treat complex diseases. Specialists now possess deeper expertise than ever before, allowing clinicians to deliver highly targeted...
Latest News
Why AI Pilots Fail in Life Sciences
Misaligned incentives, the wrong unit of work, and a probabilistic model where the process demands a reproducible one A draft annex to European GMP guidance, out for consultation until October 2025, contains the bluntest sentence yet written about AI in regulated...
Prevention by Design: How Korea’s Health System Diverges from America’s
South Korea and the United States are both wealthy, technologically sophisticated countries with excellent physicians and world-class hospitals. Yet they placed opposite structural bets on what a health system is for. America bet on treating disease as well as it can...
New Approach Methodologies: What Regulators Now Accept
New approach methodologies have moved from the margins of preclinical science to the centre of regulatory policy. Since publishing its Roadmap to Reducing Animal Testing in Preclinical Safety Studies in April 2025, the United States Food and Drug Administration has...
Evaluating Retrieval Systems for Clinical AI
Clinical decision support is not new, and it does not have to be complex to work. If anything, the simpler it is, the more likely clinicians are to use it. The best-known earlier example is the WHO surgical safety checklist, developed by a team led by Atul Gawande,...
Join The Future Of Life Sciences Media
In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters — all in real time.
Don’t wait for the media to pick up your story. Be the media.
Trending
More News
CAR-T Therapy Reaches Solid Tumours for the First Time
China's National Medical Products Administration (NMPA) approved satricabtagene autoleucel (satri-cel) on 22 June 2026, making it the world's first CAR-T cell therapy approved for a solid tumour. Developed by Shanghai-based CARsgen Therapeutics, satri-cel is cleared...
Late-Stage Obesity Drugs: 7 to Watch Beyond Ozempic
The weight-loss revolution that began with Ozempic and Wegovy is entering a more crowded and competitive phase, and the field of late-stage obesity drugs has become the most closely watched area in pharmaceutical research. Two recent milestones show how fast the...
Why Regenerative Medicine May Reshape the Future of Spinal Fusion
The repair and replacement of bone is a major clinical problem. The need for efficient treatments of spinal injuries, has become increasingly common and remains a significant challenge in the field of orthopedics. Regenerative medicine in bone repair is the use of...
CRISPR Gene Editing 2026: Rare Diseases, Cancer and Autoimmune
CRISPR gene editing in 2026 is no longer a technology to watch. It is a technology delivering results. Across three distinct disease areas, rare inherited conditions, haematologic and solid cancers, and autoimmune disease, clinical programmes are accumulating...
GroYourBiz Honours Canadian Clinical Leaders as “Champions of Change”
GroYourBiz (GYB), a leading organisation supporting female senior leaders and women-owned businesses, is proud to announce the recipients of its 2026 Champion of Change Award, three exceptional clinical leaders whose innovation and determination are transforming...
Weekly News Roundup | 22 June 2026
Life science news 22 June 2026: the FDA clears the first disease-modifying therapy for newly diagnosed childhood type 1 diabetes, the MHRA approves the UK's first cancer treatment delivered by on-body injector, and GSK wins approval for the first oral carbapenem...
AVITA Medical Presents RECELL GO U.K. Clinical Data at BBA Annual Meeting
First U.K. case series demonstrates successful use of RECELL GO® in 17 burn and reconstructive surgery patients Findings presented at the British Burn Association Annual Meeting support the role of RECELL GO in standardizing preparation of RECELL® Spray-On Skin™ Cells...
Clinical Trials Roundup | 19 June 2026
The Menarini Group and Karyopharm Therapeutics report that selinexor plus ruxolitinib improves spleen response over standard monotherapy in the Phase 3 SENTRY trial in myelofibrosis, Agios Pharmaceuticals reinforces the anti-hemolytic profile of mitapivat with new...
Nasal Photodisinfection Cuts Surgical Infections In Complex Brain Surgery
Nasal Photodisinfection Cuts Surgical Infections In Complex Brain Surgery By 78.5% at Leeds Teaching Hospitals A pilot involving 189 patients at Leeds Teaching Hospitals using nasal photodisinfection prior to complex brain procedures performed through the nose has led...
Beyond the Injection: The Future of Holistic GLP-1 Care
The rise of GLP-1 medications has changed the conversation around obesity faster than almost anything we have seen in modern medicine. What was once dismissed as a simple issue of “willpower” is finally being recognised as something far more biologically complex....
Biotech IPO Surge: 2026’s First Half Beats 2025
Update 29th July 2026: For the completed first-half picture, including the June listings and Nasdaq's H1 figures, see Biotech IPO 2026: From Drought to Record-Breaking Deals. The biotech IPO surge has turned 2026 into a comeback year, and one statistic captures it: in...
Outcomes of a Nationwide Cardiac Screening Programme – Focusing on Females
Exciting new research presented at the annual conference of the British Cardiovascular Society (BCS): 1 - 3 June 2026 According to a new, CRY-funded study (an important subsidiary of the seminal research paper published earlier this year in the Journal of the American...
CAR-T Therapy Reaches Solid Tumours for the First Time
China's National Medical Products Administration (NMPA) approved satricabtagene autoleucel (satri-cel) on 22 June 2026, making it the world's first CAR-T cell therapy approved for a solid tumour. Developed by Shanghai-based CARsgen Therapeutics, satri-cel is cleared...
Late-Stage Obesity Drugs: 7 to Watch Beyond Ozempic
The weight-loss revolution that began with Ozempic and Wegovy is entering a more crowded and competitive phase, and the field of late-stage obesity drugs has become the most closely watched area in pharmaceutical research. Two recent milestones show how fast the...
Why Regenerative Medicine May Reshape the Future of Spinal Fusion
The repair and replacement of bone is a major clinical problem. The need for efficient treatments of spinal injuries, has become increasingly common and remains a significant challenge in the field of orthopedics. Regenerative medicine in bone repair is the use of...
CRISPR Gene Editing 2026: Rare Diseases, Cancer and Autoimmune
CRISPR gene editing in 2026 is no longer a technology to watch. It is a technology delivering results. Across three distinct disease areas, rare inherited conditions, haematologic and solid cancers, and autoimmune disease, clinical programmes are accumulating...
GroYourBiz Honours Canadian Clinical Leaders as “Champions of Change”
GroYourBiz (GYB), a leading organisation supporting female senior leaders and women-owned businesses, is proud to announce the recipients of its 2026 Champion of Change Award, three exceptional clinical leaders whose innovation and determination are transforming...
Weekly News Roundup | 22 June 2026
Life science news 22 June 2026: the FDA clears the first disease-modifying therapy for newly diagnosed childhood type 1 diabetes, the MHRA approves the UK's first cancer treatment delivered by on-body injector, and GSK wins approval for the first oral carbapenem...
AVITA Medical Presents RECELL GO U.K. Clinical Data at BBA Annual Meeting
First U.K. case series demonstrates successful use of RECELL GO® in 17 burn and reconstructive surgery patients Findings presented at the British Burn Association Annual Meeting support the role of RECELL GO in standardizing preparation of RECELL® Spray-On Skin™ Cells...
Clinical Trials Roundup | 19 June 2026
The Menarini Group and Karyopharm Therapeutics report that selinexor plus ruxolitinib improves spleen response over standard monotherapy in the Phase 3 SENTRY trial in myelofibrosis, Agios Pharmaceuticals reinforces the anti-hemolytic profile of mitapivat with new...
Nasal Photodisinfection Cuts Surgical Infections In Complex Brain Surgery
Nasal Photodisinfection Cuts Surgical Infections In Complex Brain Surgery By 78.5% at Leeds Teaching Hospitals A pilot involving 189 patients at Leeds Teaching Hospitals using nasal photodisinfection prior to complex brain procedures performed through the nose has led...
Beyond the Injection: The Future of Holistic GLP-1 Care
The rise of GLP-1 medications has changed the conversation around obesity faster than almost anything we have seen in modern medicine. What was once dismissed as a simple issue of “willpower” is finally being recognised as something far more biologically complex....
Biotech IPO Surge: 2026’s First Half Beats 2025
Update 29th July 2026: For the completed first-half picture, including the June listings and Nasdaq's H1 figures, see Biotech IPO 2026: From Drought to Record-Breaking Deals. The biotech IPO surge has turned 2026 into a comeback year, and one statistic captures it: in...
Outcomes of a Nationwide Cardiac Screening Programme – Focusing on Females
Exciting new research presented at the annual conference of the British Cardiovascular Society (BCS): 1 - 3 June 2026 According to a new, CRY-funded study (an important subsidiary of the seminal research paper published earlier this year in the Journal of the American...
Featured Articles
Further News
Why AI May Increase Cognitive Burden Before Reducing It
It seems that artificial intelligence is being proposed as an answer to what could be considered as one of the most serious problems facing the life sciences sector – the problem of information overload. There has never been as much data, documentation, literature,...
The Seduction of Ease: Burnout, AI, and Human Leadership in Life Sciences
Life sciences exist to do something extraordinary. Their applied solutions seek to understand biology and improve health and the quality of life for humans, animals, and plants. That is not a small mission; at its core, it is deeply human. It is the kind of mission...
CagriSema: Strong Obesity Data, but can it Beat Tirzepatide?
CagriSema, the once-weekly obesity therapy from Novo Nordisk, has spent more than a year as the most closely watched candidate in metabolic medicine. The combination of cagrilintide and semaglutide promised weight loss beyond what either molecule could achieve alone....
Improving Oncolytic Virus Development for Cancer Immunotherapy Research
Oncolytic virus development is gaining increasing attention in cancer immunotherapy research because of its ability to combine direct tumor cell killing with immune activation. Unlike conventional therapeutic strategies that focus on one pathway or one target,...
Will Artificial Intelligence Replace Medical Science Liaisons?
What Global Surveys of Medical Affairs Professionals Reveal Artificial intelligence (AI) is rapidly transforming the pharmaceutical industry, prompting many Medical Affairs professionals to ask whether some roles may eventually become obsolete. Headlines regularly...
GLP-1 Uptake by Country: Where Ozempic and Mounjaro are Booming in 2026
The global market for glucagon-like peptide-1 (GLP-1) receptor agonists has entered a new phase. What began as a breakthrough in type 2 diabetes management has become one of the defining pharmaceutical stories of the decade. In 2025, the GLP-1 receptor agonist market...
AI’s Next Leap in Biopharma: From Acceleration to Intelligence in Partnership
Artificial intelligence has already changed the rhythm of discovery in biopharma. Algorithms can screen millions of molecules, identify trial candidates, and forecast supply chains with extraordinary speed. Yet speed is not the same as progress. The next chapter of AI...
Weekly News Roundup | 15 June 2026
Life science news 15 June 2026: GSK's $10.6 billion Nuvalent acquisition headlines a blockbuster M&A week, the MHRA approves the UK's first oral weight-loss semaglutide tablet, and the FDA clears a new adjuvant combination for kidney cancer in a landmark week for...
What GLP-1 Patients Don’t Know About Muscle Loss and Why It Matters
GLP-1 receptor agonists are transforming obesity treatment. But the clinical conversation about lean muscle preservation is lagging behind the prescribing rate, and that gap has real consequences for patients, says Omar el-Gohary. There is a version of the GLP-1...
Why Europe’s Precision Oncology Trials Keep Stalling
Precision medicine works when the right biomarker test reaches the right patient in time. In Europe, the regulatory plumbing is making that harder than it should be. At the 16th Clinical Biomarkers & CDx Summit in London in March 2026, I discussed lessons from MDx...
Complement Inhibitor Setback: Sanofi Halts CIDP Study
Sanofi has halted a late-stage trial of its experimental complement inhibitor riliprubart in chronic inflammatory demyelinating polyneuropathy (CIDP), a setback that analysts say could create volatility across the wider complement inhibitor field. The company said in...
Clinical Trials Roundup | 12 June 2026
Survodutide delivers dual Phase 3 success in obesity and metabolic liver disease at ADA 2026, secukinumab becomes the first targeted biologic to demonstrate sustained remission in polymyalgia rheumatica, dapirolizumab pegol meets its Phase 3 primary endpoint in...
Further News
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.
Don’t wait for the media to pick up your story. Be the media.
See More Articles
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.